Telemedicine and Trust
Telemedicine may be the future of healthcare. Exactly how that future will manifest varies widely. But predicting the future based...
Microfinance in Modern Healthcare
Microfinance has changed the world for good, helping millions support their healthcare costs. But the future of modern healthcare depends less...
When Will COVID-19 Functionally End?
The year 2020 is finally coming to an end, but the end of the pandemic seems nowhere in sight. While...
When Healthcare Law and Ethics Conflict
Most assume law to be a reflection of the ethics within a society. But in healthcare, law and ethics are...
The Pace of Healthcare
All things move at their own pace. A statement more likely to be made by a philosopher than by a...
Vaccine True Efficacy
The pandemic has accelerated the adoption of consumerism principles throughout healthcare. But not everybody is adopting these principles uniformly. And...
COVID-19 & The Future of Online News
The recent lockdowns and ongoing restrictions have brought about an increased interest in health and science news online. But a...
Quantum Healthcare
Quantum mechanics has been applied to many fields of science, including biology, leading to recent breakthroughs among longstanding problems within...
Marketing Virality
A hospital executive struggles to balance the accurate reporting of viral incidence rates with the business needs of his hospital...
Great Expectations
Bob the pharmacist prides himself on his dedication to his patients, and his commitment to his job. But when he...
Patient Schematics
For many physicians, their patients come to symbolize many things. For this particular physician, the patients appear as different symbols...
A Vaccine Mandate By Any Other Name
A rose by any other name would smell just as sweet. And a vaccine mandate by any other name would...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more